Hypertension unchecked among uninsured
Adults without health insurance are more likely to have undiagnosed hypercholesterolemia and hypertension than those with health insurance
NON-ELDERLY ADULTS without health insurance are far more likely to have undiagnosed-and consequently uncontrolled-hypercholesterolemia and hypertension than those with health insurance, according to a new analysis of Centers for Disease Control data.
"The analysis is really just one more indication of the many ways lack of health insurance is harmful to a person's health," says Andrew Wilper, MD, a professor in the Department of Medicine, University of Washington, who has conducted similar studies in the past.
The latest research, based on 2005-2008 data from the CDC's National Health and Nutrition Examination Survey (NHANES) found uninsured adults between the ages of 20 and 64 were about twice as likely to suffer from undiagnosed hypercholesterolemia or hypertension as their insured peers. In addition to interviews conducted in participants' homes, the NHANES survey includes standardized physical examinations conducted in mobile examination centers and laboratory tests utilizing blood and urine specimens provided by participants, which enable researchers to identify individuals with previously undiagnosed conditions.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
